Concordia International (TSX: CXR), the Healthcare company, has received a rating update from a Wall Street analyst on September 11. Bloom Burton’s analyst David Martin, PhD, MBA reiterates their Hold rating on the shares.
Concordia International has an analyst consensus of Hold.
Concordia International’s market cap is currently C$4.14M and has a P/E ratio of 0. The company has a Price to Book ratio of -0.
Concordia International Corp. is a pharmaceutical company, which engages in owning and licensing a diversified portfolio of branded and generic prescription products. It operates through the Concordia North America and Concordia International segments.
The company’s shares closed on Friday at C$24.20, close to its 52-week low of C$19.02.